Fundraising FoxBlueYard Capital — 2023 Investments
10 investments dated 2023 · listed companies and verified rows first · show all
Chemify builds automated chemical synthesis systems combining chemistry, AI, and robotics to digitize molecular design and manufacturing.
AI & Machine LearningBiotechDeep TechGlasgow, GB
Lee Cronin(Founder)inLeroy Cronin(Founder)
Co-investorsInsight PartnersAlix VenturesCreator FundEos AdvisoryHAWKTAILHorizons Ventures+12 more
VSParticle develops binder-free nanoprinting technology based on spark ablation to produce and deposit ultra-pure nanoporous layers from 40+ elements, and sells automated tools and a deposition service to academia and R&D customers.
CleantechDeep TechHardwareNew MaterialsDelft, NL
Andreas Schmidt-Ott(Founder)in
Co-investorsNordicNinjaAmadeus Capital PartnersHermann Hauser Investment
Vectary is a browser-based 3D design and collaboration platform used across the product development process from concept to market.
Creator EconomyFuture of WorkSaaSRedwood City, US
Pavol Sovis(Director)inMichal Koor(Executive Officer, Director)inTed Persson(Director)in
BoardCiaran OLeary(Director)
Board seatCiaran O'Leary· per SEC Form D
Co-investorsNeulogy VenturesEQT Ventures
Biomia is a biotechnology company using biology, chemistry, and pharmacoengineering to develop a new generation of central nervous system (CNS) therapeutics.
BiotechHealthtech
Co-investorsAmino CollectiveNucleus Capital
Creasallis develops CreaTap, a patented "plug-and-play" antibody modification technology that improves the penetration of antibody-based drugs into solid tumours, applicable to monoclonal, bispecific, and antibody-drug conjugates.
Biotech
Zahra Jawad(Founder)in
Co-investorsKdT VenturesPace VenturesZAKA VC
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue.
AI & Machine LearningBiotechDeep TechTolland, US
John Deacon(Executive Officer, Director)Colin J. Foster(Executive Officer, Director)
BoardJason Whitmire(Director)inAlex Brunicki(Director)in
Co-investorsBackedConnecticut Innovations
Ingonyama develops cryptography acceleration technology, including ICICLE, a library that speeds up algorithms and protocols such as zero-knowledge proofs across compute backends like CPUs, GPUs, Apple Silicon, and its ZPU hardware.
Crypto & Web3Deep TechDeveloper Tools
Co-investorsIOSG VenturesMaven 11RockawayXSamsung NextZero Knowledge Validator (ZKV)Geometry+2 more
Rapidata provides human-powered evaluation services for generative AI models, enabling teams to assess subjective quality criteria like naturalness, coherence, cultural fit, and safety at scale.
AI & Machine LearningData & InfrastructureDeveloper Tools
Jason(Founder & Head)
Co-investorsCanaan PartnersIA Ventures
Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development.
AI & Machine LearningBiotechDeep TechHealthtechOxford, GB
Miroslav Gasparek(Founder)inMarian Kupculak(Founder)in
BoardVishal Gulati(Director)Joel Schoppig(Director)
Co-investorsAmino CollectiveCivilization Ventures Management, LlcIn-Q-TelKAYARecode VenturesTech Horizons+13 more
Visolis engineers industrial-scale alternatives to traditional fuels and chemicals through biology and chemistry, producing MEV as a non-toxic, biodegradable drop-in replacement that can be manufactured in distributed facilities worldwide.
Advanced ManufacturingCleantechEnergy
Co-investorsCreative VenturesFirst Bight VenturesGlobal BrainStartXZeon Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.